

In the Claims

## Claims 1-14 (Cancelled)

Claim 15 (Currently amended): A method for reducing surgical adhesion formation, comprising administering a therapeutic formulation comprising TIMP-1 antibodies, or Fab fragments thereto, to a patient at risk of surgical adhesion formation, wherein the therapeutic formulation is administered in an amount effective to reduce the local level of TIMP-1 and surgical adhesion formation.

Claim 16 (Previously added): The method of claim 15, wherein the therapeutic formulation comprises TIMP-1 antibodies, and wherein the TIMP-1 antibodies are monoclonal antibodies.

Claim 17 (Previously added): The method of claim 15, wherein the therapeutic formulation comprises TIMP-1 antibodies, and wherein the TIMP-1 antibodies are polyclonal antibodies.

Claim 18 (Previously added): The method of claim 15, wherein the therapeutic formulation further comprises a suitable carrier.

Claim 19 (Previously added): The method of claim 18, wherein the carrier is hyaluronic acid.

## Claims 20-22 (Cancelled)

Claim 23 (Currently amended): The method of claim 15, wherein the surgical adhesion is a peritoneal adhesion.

## Claim 24 (Cancelled)

Claim 25 (Currently amended): The method of claim 15, wherein the surgical adhesion is a surgical adhesion of intra-peritoneal tissue selected from the group consisting of parietal peritoneum, uterus, fallopian tube, ovary, bowel, and omentum.

Claim 26 (Cancelled)